Friday, 22 Jun 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
15 Nov 2017 Social Abbvies 9/17 settlement with Amgen that allows Amgens adalimumab biosimilar (Amjevita) to begin sales in EU Oct 20… https://t.co/S21dfEjadJ
13 Nov 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6… https://t.co/m7LtJVAnfQ
08 Nov 2017 Social RT @Janetbirdope: No difference in lung safety of Abatacept and TNFI and one study of more ILD with IFX vs ABA #137. #acr17 @rheumnow #526…
08 Nov 2017 Social RT @Janetbirdope: #GAMECHANGER. Switching to a biosimilar in British registry shows no attenuation. #acr17 @rheumnow #2439 https://t.co/w4q…
07 Nov 2017 Social RT @Janetbirdope: #GAMECHANGER. If not responding to tociluzimab in RA you can respond to switch to 200 mg sarilab #acr17 @rheumnow #2468 h…
07 Nov 2017 Social RT @philipcrobinson: New Jak-1 selective inhibitor ABT-494 doesn’t look too bad #ACR17 @RheumNow https://t.co/sAHVqJr31a
07 Nov 2017 Social RT @KDAO2011: Plenary #2754 tailored RTX based on +ANCA +CD19 B cells performed as well as scheduled RTX for AAV #ACR17 @rheumnow
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
07 Nov 2017 Social RT @CCalabreseDO: Effect of live HZ vaccine in MTX-IR w/RA getting tofa or ADA +/- MTX: well-tolerated, higher HZ rates in tofa+MTX #2393 #…
07 Nov 2017 Social RT @japaoli19: Benefits of IL6 blockade on insulin resistance in RA #1400 #ACR17 @RheumNow https://t.co/tYFYRnRlof
07 Nov 2017 Social RT @CCalabreseDO: R. Fleischmann regarding biosimilars, “there are not savings for the patient” @RheumNow #ACR17 https://t.co/qdwVqsV3Zq
06 Nov 2017 Social RT @regeneron: In rheumatoid #arthritis, chronically elevated IL-6 levels may drive inflammation & joint destruction. #ACR17 https://t.co/h…
06 Nov 2017 Social RT @_connectedcare: Here’s a list of other biologics being trialed in GCA. An exciting time #acr17 @RheumNow https://t.co/nqNtRHSSni
06 Nov 2017 Social RT @LCalabreseDO: Stefan Rose-John knocks down vitals of cis/trans IL6 signaling at #ACR17- Rheum’s need 2 know! @HealioRheum @Actemra @iKe…
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
05 Nov 2017 Social RT @_connectedcare: Impressive result for Mepolizumab in EGPA #ACR17 @rheumnow https://t.co/YhqvGLwpMu
05 Nov 2017 Social RT @WIRheum: Great debate: patient and provider preferences around biosimilar use from @RheumNow survey #ACR17 https://t.co/MgBXZ9gyeV
05 Nov 2017 Social RT @WIRheum: Great Debate "No evidence" that biosimilar is non-inferior to originator #ACR17 @RheumNow https://t.co/mHyoGF4ULS
05 Nov 2017 Social Year in Review. Dan Solomon reviews and shows no cancer risk with Biologics. #ACR17 https://t.co/wra8tf1viY
05 Nov 2017 News BMS Featured Presentations from ACR 2017